IL15 and neoplasm: Here, for the first time, we describe the anti-tumor efficacy of subcutaneously administered IL-15 superagonist N-803 (previously known as ALT-803) in combination with an αPD-L1 monoclonal antibody in murine TN breast and colon carcinoma models.